-+ 0.00%
-+ 0.00%
-+ 0.00%

Oramed Pharma Closes Strategic Investment In Alpha Tau Medical; Oramed Affiliate Purchases About 14.1M Alpha Tau's Ordinary Shares $2.612/Shr

Benzinga·04/28/2025 13:04:26
Listen to the news

Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW))), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.  

The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau intends to use the net proceeds from the offering for general corporate purposes, including research and development-related purposes in connection with its product candidates, for expansion of its manufacturing capabilities and for potential commercialization of its product candidates.